Tajiri Kensuke, Sudo Tomoya, Ishi Kazuo, Kawahara Akihiko, Nagasu Sachiko, Shimomura Susumu, Yuge Kotaro, Katagiri Mitsuhiro, Yomoda Takato, Fujiyoshi Kenji, Kenichi Koshi, Ohchi Takafumi, Yoshida Takefumi, Mizobe Tomoaki, Fujita Fumihiko, Akiba Jun, Akagi Yoshito
Department of Surgery, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan.
Research Center for Innovative Cancer Therapy, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan.
Mol Clin Oncol. 2021 May;14(5):98. doi: 10.3892/mco.2021.2260. Epub 2021 Mar 12.
Signet ring cell carcinoma (SRCC) is a rare pathological type of colorectal cancer, of which the clinicopathological features and genetic background have not yet been fully investigated. Previous research has focused on the optimization of colorectal cancer treatment utilizing consensus molecular subtyping (CMS). However, it is not known what type of CMS would be designated to SRCC treatment. In the current study, of 1,350 patients diagnosed with colorectal cancer who underwent surgery, 14 were diagnosed with SRCC. The case-control cohort that fit the clinical background of the SRCC case was constructed. Statistical comparison between the SRCC group and the case-control cohort was performed among clinicopathological variables. SRCC and well to moderately adenocarcinoma case mRNA were submitted to microarray analysis and CMS analysis. Compared with the case-control cohort, the SRCC group was located more in the right-sided colon, the lymphatic invasion was more severe and the peritoneal dissemination was more frequent. The cancer-specific survival and the progression-free survival were significantly worse in the SRCC group compared with the case-control cohort. Microarray and CMS analysis identified that one SRCC case was significantly well assigned in the CMS 4 group and the other case was assigned in the CMS 1 group. Gene set analysis revealed the upregulation of EMT related genes and the downregulation of fatty acid, glycolysis, differentiation, MYC, HNF4A, DNA repair genes. In conclusion, the clinical characteristics of SRCC are severe but there is a possibility of the presence of different phenotypes according to CMS analysis.
印戒细胞癌(SRCC)是一种罕见的结直肠癌病理类型,其临床病理特征和基因背景尚未得到充分研究。以往的研究主要集中在利用共识分子亚型(CMS)优化结直肠癌治疗。然而,尚不清楚SRCC治疗应指定何种CMS类型。在本研究中,1350例接受手术的结直肠癌患者中,14例被诊断为SRCC。构建了符合SRCC病例临床背景的病例对照队列。对SRCC组和病例对照队列进行临床病理变量的统计学比较。将SRCC和高分化至中分化腺癌病例的mRNA进行微阵列分析和CMS分析。与病例对照队列相比,SRCC组更多位于右半结肠,淋巴侵犯更严重,腹膜播散更频繁。与病例对照队列相比,SRCC组的癌症特异性生存率和无进展生存率显著更差。微阵列和CMS分析确定,1例SRCC病例在CMS 4组中分配良好,另1例在CMS 1组中。基因集分析显示EMT相关基因上调,脂肪酸、糖酵解、分化、MYC、HNF4A、DNA修复基因下调。总之,SRCC的临床特征严重,但根据CMS分析可能存在不同表型。